Treatment considerations for the pharmacotherapeutic management of constipation associated with colonic diverticular disease [0.03%]
药物治疗结肠憩室病相关性便秘的考虑因素
Gabrio Bassotti,Antonio Tursi,Fotios S Fousekis et al.
Gabrio Bassotti et al.
Evaluating mitapivat for the treatment of alpha or beta thalassemia [0.03%]
评估mitapivat治疗α或β地中海贫血的效果
Antonis Kattamis,Konstantinos Bistas,Vangelis Mitros et al.
Antonis Kattamis et al.
Introduction: Thalassemia is a group of diverse genetic disorders with worldwide distribution that affects hemoglobin synthesis. Until recently, the therapeutic approach to thalassemia was symptomatic, relying on red bloo...
Baxdrostat and selective aldosterone synthase inhibition in hard-to-control hypertension: mechanism, evidence, safety, and future clinical positioning [0.03%]
巴索 drostat 和醛固酮合成酶选择性抑制剂在难治性高血压中的机制、证据、安全性及未来临床定位
Aziz Ullah
Aziz Ullah
Introduction: Hard-to-control hypertension remains a major therapeutic problem despite wide availability of inexpensive antihypertensive drugs. Aldosterone dysregulation contributes to sodium retention, vascular injury, r...
Do sigma-1 receptor agonists offer therapeutic promise for Alzheimer's disease? [0.03%]
σ-1受体激动剂能成为治疗阿尔茨海默病的药物吗？
Francesco Panza,Vittorio Dibello,Antonio Daniele et al.
Francesco Panza et al.
Introduction: Alzheimer's disease (AD) remains a major unmet medical need despite recent advances in amyloid-targeting therapies. The modest efficacy, safety concerns, and limited accessibility of monoclonal antibodies hi...
Gepotidacin in oral antibacterial pharmacotherapy: efficacy, safety, and clinical positioning [0.03%]
口服抗生素治疗中的 gepotidacin：疗效、安全性及临床定位
Muhammad Saeed Akhtar
Muhammad Saeed Akhtar
Introduction: Rising antimicrobial resistance and limited innovation in oral antibacterial therapy continue to complicate treatment of common outpatient infections. Gepotidacin (Blujepa) is an oral triazaacenaphthylene an...
Low-dose colchicine for atherosclerotic cardiovascular disease and the return of inflammation-targeted pharmacotherapy [0.03%]
低剂量秋水仙碱治疗动脉粥样硬化性心血管病与炎症靶向药物治疗的回归
Sajid Ali,Muhammad Siraj
Sajid Ali
Introduction: Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of major cardiovascular events despite standard therapies. Residual inflammatory risk has emerged as an important therapeutic target, bu...
Selecting optimal therapy in the evolving therapeutic landscape of metastatic pheochromocytoma and paraganglioma [0.03%]
在转移性嗜铬细胞瘤和副神经节瘤治疗格局中选择最佳疗法
Moza Hamoud,Victor M Samperio,Aishwarya Ghonge et al.
Moza Hamoud et al.
Current perspectives on β2-adrenergic receptor agonists in asthma: navigating from track to track within GINA recommendations [0.03%]
哮喘β2-肾上腺素受体激动剂的再思考：在GINA指南轨道上的切换
Luigino Calzetta,Paola Rogliani
Luigino Calzetta
Introduction: Asthma treatment has long relied on short-acting β2-adrenergic receptor (β2-AR) agonists (SABA) such as salbutamol for as-needed relief, often without concurrent anti-inflammatory therapy. Emerging data li...
Beyond the primary endpoint: what VICTOR really tells us about vericiguat [0.03%]
超越主要研究终点：VICTOR研究如何从整体上诠释维立西呱的作用？
Bianca Larroux,Flavio Tangianu,Aldo Bonaventura
Bianca Larroux
Introduction: The VICTOR trial evaluated vericiguat in stable, ambulatory HFrEF patients without recent WHF. Its primary composite endpoint of CV death or HF hospitalization resulted neutral. Yet, a significant reduction ...
Current and emerging pharmacotherapy for rosacea: a misunderstood and undertreated condition [0.03%]
玫瑰痤疮的当前及未来的药物治疗：一种被误解和忽视的皮肤病
Nashali Vescovacci,Liddy Malone,Chenan A Huang et al.
Nashali Vescovacci et al.
Introduction: Rosacea is a chronic inflammatory skin disease characterized by heterogeneous features, including erythema, telangiectasias, papules, pustules, ocular symptoms, and phymatous changes, which can impact qualit...